Annovis Bio Inc. (NYSE: ANVS) Presented Recent Achievements and Strategic Direction at H.C. Wainwright Investment Conference
- The event was attended by Annovis Founder, President and CEO Maria L. Maccecchini, Ph.D. Dr. Maccecchini discussed the company’s notable achievements and plans for the future and held a Q&A session with attendees.
- The company CEO also participated in an expert panel discussing innovative non-amyloid approaches in Alzheimer’s disease.
- Recent clinical trials of the company’s lead compound buntanetap obtained encouraging results and was shown to improve cognition in both Alzheimer’s and Parkinson’s patients.
Annovis Bio (NYSE: ANVS), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer’s disease (“AD”) and Parkinson’s disease (“PD”), participated in the H.C. Wainwright 26th Annual Global Investment Conference, held virtually, as well as in-person at the Lotte New York Palace Hotel in New York City, Sept. 9-11, 2024 (https://nnw.fm/kDnr8 ).
The company was represented at the event by Founder, President and CEO Maria L. Maccecchini, Ph.D., who gave a detailed presentation highlighting Annovis’s recent achievements, followed by a Q&A session on Sept. 10. Dr. Maccecchini also participated in a panel discussion focusing on innovative non-amyloid approaches in Alzheimer’s disease, featuring representatives from Annovis, Anavex Life Sciences Corp. (NASDAQ: AVXL) and Longeveron Inc. (NASDAQ: LGVN).
Dr. Maccecchini’s presentation included an overview of the company’s recent advancements and strategic direction, coming after several productive months for Annovis, with encouraging data on lead compound buntanetap’s performance in three pivotal studies. Buntanetap works by targeting multiple pathways involved in neurodegenerative diseases. It inhibits the production of neurotoxic proteins that lead to the death of neurons, thereby slowing or stopping disease progression.
The three recent studies that yielded encouraging results include:
Phase 2/3 Alzheimer’s Disease Clinical Trial: Data from this study showed that buntanetap significantly improved cognition in patients with early AD, with a 3.3-point improvement on the ADAS-Cog11 test after three months of treatment, compared to a 0.3-point improvement in the placebo group. A later analysis on June 11 demonstrated that buntanetap was effective in improving cognition among high-risk APOE4 carriers, showing a 3.15-point improvement. It also showed that buntanetap was as safe in APOE4 carriers as non-carriers, an impressive advantage over existing disease-modifying therapies.
Phase 3 Parkinson’s Disease Clinical Trial: Study data indicated that buntanetap led to significant improvements in both the Unified Parkinson’s Disease Rating Scale (“MDS-UPDRS”) and cognition across several PD subpopulations. Buntanetap showed a strong response in individuals diagnosed with PD for more than three years as well as in those with postural instability and gait disorder. The lead compound was also found to halt cognitive decline in all enrolled patients and improved cognition in those with mild dementia.
Combination Trial with GLP-1 Agonist Dulaglutide: Preclinical data demonstrated that buntanetap synergistically enhances cognition beyond normal levels, when used in combination with the glucagon-like peptide 1 (“GLP-1”) agonist dulaglutide (“Trulicity”(R)) in a mouse model of AD.
Among other notable recent achievements was the introduction of a new crystalline form of buntanetap with improved properties, offering significant advantages over the less structured, old semi-crystalline form, including better solubility and stability as well as an additional 20 years of patent life.
Annovis filed the new crystalline form with the International Patent Cooperation Treaty and a provisional patent for the manufacturing of this crystalline form, covering the entire synthesis process. The company also received approval from the Food and Drug Administration to continue the clinical development with this new form of buntanetap. Additionally, the company was granted a U.S. patent for the use of buntanetap in the treatment of acute traumatic brain injury, expanding its coverage, since acute indication claims had been previously granted in Europe and worldwide.
“These milestones position us strongly as we move closer to providing much-needed treatments to patients,” Dr. Maccecchini said in a recent press release, commenting on the business updates (https://nnw.fm/bCIUb ).
For more information about the company, visit www.AnnovisBio.com, and social channels LinkedIn, X and YouTube.
NOTE TO INVESTORS: The latest news and updates relating to ANVS are available in the company’s newsroom at https://nnw.fm/ANVS
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or republished: http://NNW.fm/Disclaimer
- The event was attended by Annovis Founder, President and CEO Maria L. Maccecchini, Ph.D. Dr. Maccecchini discussed the company’s notable achievements and plans for the future and held a Q&A session with attendees.
- The company CEO also participated in an expert panel discussing innovative non-amyloid approaches in Alzheimer’s disease.
- Recent clinical trials of the company’s lead compound buntanetap obtained encouraging results and was shown to improve cognition in both Alzheimer’s and Parkinson’s patients.
Annovis Bio (NYSE: ANVS), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer’s disease (“AD”) and Parkinson’s disease (“PD”), participated in the H.C. Wainwright 26th Annual Global Investment Conference, held virtually, as well as in-person at the Lotte New York Palace Hotel in New York City, Sept. 9-11, 2024 (https://nnw.fm/kDnr8 ).
The company was represented at the event by Founder, President and CEO Maria L. Maccecchini, Ph.D., who gave a detailed presentation highlighting Annovis’s recent achievements, followed by a Q&A session on Sept. 10. Dr. Maccecchini also participated in a panel discussion focusing on innovative non-amyloid approaches in Alzheimer’s disease, featuring representatives from Annovis, Anavex Life Sciences Corp. (NASDAQ: AVXL) and Longeveron Inc. (NASDAQ: LGVN).
Dr. Maccecchini’s presentation included an overview of the company’s recent advancements and strategic direction, coming after several productive months for Annovis, with encouraging data on lead compound buntanetap’s performance in three pivotal studies. Buntanetap works by targeting multiple pathways involved in neurodegenerative diseases. It inhibits the production of neurotoxic proteins that lead to the death of neurons, thereby slowing or stopping disease progression.
The three recent studies that yielded encouraging results include:
Phase 2/3 Alzheimer’s Disease Clinical Trial: Data from this study showed that buntanetap significantly improved cognition in patients with early AD, with a 3.3-point improvement on the ADAS-Cog11 test after three months of treatment, compared to a 0.3-point improvement in the placebo group. A later analysis on June 11 demonstrated that buntanetap was effective in improving cognition among high-risk APOE4 carriers, showing a 3.15-point improvement. It also showed that buntanetap was as safe in APOE4 carriers as non-carriers, an impressive advantage over existing disease-modifying therapies.
Phase 3 Parkinson’s Disease Clinical Trial: Study data indicated that buntanetap led to significant improvements in both the Unified Parkinson’s Disease Rating Scale (“MDS-UPDRS”) and cognition across several PD subpopulations. Buntanetap showed a strong response in individuals diagnosed with PD for more than three years as well as in those with postural instability and gait disorder. The lead compound was also found to halt cognitive decline in all enrolled patients and improved cognition in those with mild dementia.
Combination Trial with GLP-1 Agonist Dulaglutide: Preclinical data demonstrated that buntanetap synergistically enhances cognition beyond normal levels, when used in combination with the glucagon-like peptide 1 (“GLP-1”) agonist dulaglutide (“Trulicity”(R)) in a mouse model of AD.
Among other notable recent achievements was the introduction of a new crystalline form of buntanetap with improved properties, offering significant advantages over the less structured, old semi-crystalline form, including better solubility and stability as well as an additional 20 years of patent life.
Annovis filed the new crystalline form with the International Patent Cooperation Treaty and a provisional patent for the manufacturing of this crystalline form, covering the entire synthesis process. The company also received approval from the Food and Drug Administration to continue the clinical development with this new form of buntanetap. Additionally, the company was granted a U.S. patent for the use of buntanetap in the treatment of acute traumatic brain injury, expanding its coverage, since acute indication claims had been previously granted in Europe and worldwide.
“These milestones position us strongly as we move closer to providing much-needed treatments to patients,” Dr. Maccecchini said in a recent press release, commenting on the business updates (https://nnw.fm/bCIUb ).
For more information about the company, visit www.AnnovisBio.com, and social channels LinkedIn, X and YouTube.
NOTE TO INVESTORS: The latest news and updates relating to ANVS are available in the company’s newsroom at https://nnw.fm/ANVS
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or republished: http://NNW.fm/Disclaimer
